BioSig Technologies (BSGM +2%) announces that
subsidiary ViralClear Pharmaceuticals will conduct a Phase 2 clinical
trial at Mayo Clinic evaluating broad-spectrum antiviral Vicromax
(merimepodib) in COVID-19 patients.
An IND should be filed with the FDA in the coming weeks aimed at launching the study in May.
Merimepodib puts the brakes on the proliferation of the virus by inhibiting the action of enzymes called polymerases that play an essential role in viral RNA replication.
https://seekingalpha.com/news/3561333-biosig-to-launch-study-of-covidminus-19-antiviral-mayo-clinic
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.